Atezolizumab combination improves PFS for advanced NSCLC patients
Findings from a recent study demonstrate that the use of atezolizumab, a PD-L1 inhibitor, in…
Browsing: PD-L1 inhibitor
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- The OJC Episode 23: ASCO GI Special
- Human pancreatic cancer model offers new opportunities for testing drugs
- Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
- Poor brain cancer survival outcomes on the rise
- Oesophageal cancer: 3-D printed stents deliver breakthrough treatment
- Potential therapeutic targets to inhibit colorectal cancer progression
- UK Lockdowns: Significant reduction in new cancer diagnoses
- More than half of cancer survivors have underlying medical conditions associated with severe COVID
